Adiponectin, cardiovascular disease, chronic kidney disease: emerging data on complex interactions

Area of Science:

• Internal Medicine
• Pediatrics
• Nephrology

Background:

• Adiponectin is recognized for its role in metabolism and inflammation, generally acting as a protective factor against cardiovascular disease (CVD).
• Low adiponectin levels are consistently linked to increased CVD morbidity and mortality in adults, particularly those with obesity and type 2 diabetes.
• In contrast, patients with chronic kidney disease (CKD) exhibit elevated adiponectin levels despite a higher risk of adverse cardiovascular outcomes.

Purpose of the Study:

• To review the current understanding of adiponectin in the pediatric population.
• To examine the association between adiponectin levels and CVD risks in children and adults with CKD.
• To explore the paradoxical relationship between elevated adiponectin and cardiovascular risk in the context of CKD.

Main Methods:

• Literature review of studies on adiponectin in pediatric populations.
• Analysis of research investigating adiponectin's role in cardiovascular risk in CKD patients (pediatric and adult).
• Discussion of the implications of differing adiponectin levels and their association with CVD in CKD.

Main Results:

• Adiponectin is generally considered protective against CVD in the general population.
• Elevated adiponectin levels in CKD patients are associated with increased cardiovascular risk, challenging its protective role.
• Standardized normative values for adiponectin are lacking, hindering direct comparisons across studies.

Conclusions:

• The established protective role of adiponectin against CVD may not apply in the context of CKD.
• Further research is needed to elucidate the complex role of adiponectin in pediatric and adult CKD patients.
• The paradoxical findings highlight the need for careful interpretation of adiponectin levels in CKD and its association with cardiovascular outcomes.